Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes
Eledon Pharmaceuticals announced promising preliminary results for tegoprubart, an investigational anti-CD40L antibody, in an islet transplant trial for type 1 diabetes. Conducted at the University of Chicago Medicine’s Transplant Institute, the trial showed all six patients in the preliminary cohort achieved insulin independence. The study is funded by Breakthrough T1D, with further research support committed. Results were presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium in Los Angeles.
Eledon Pharmaceuticals Inc. has announced preliminary results from an ongoing investigator-initiated clinical trial evaluating tegoprubart, an investigational anti-CD40 Ligand (anti-CD40L) antibody, as the core immunosuppressant in islet transplantation for individuals with type 1 diabetes. The trial, conducted at the University of Chicago Medicine’s Transplant Institute, is assessing a tacrolimus-free immunosuppression regimen to prevent islet transplant rejection. Preliminary data from the first six patients were presented at the Rachmiel Levine-Arthur Riggs Diabetes Research Symposium, held November 14-17, 2025, at City of Hope in Los Angeles, California. All six subjects in the preliminary cohort achieved insulin independence. The study is funded by Breakthrough T1D, which has also committed to support further research on tegoprubart in this context. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9578266-en) on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
